Information Journal Paper
APA:
Copy. (2017). Characterization of folate receptor alpha (FRα ) expression in archival tumor and biopsy samples in a phase I study of mirvetuximab soravtansine, a FRα-targeting antibody-drug conjugate (ADC), in relapsed epithelial ovarian cancer patients. GYNECOLOGIC ONCOLOGY, 145(-), 0-0. SID. https://sid.ir/paper/746569/en
Vancouver:
Copy. Characterization of folate receptor alpha (FRα ) expression in archival tumor and biopsy samples in a phase I study of mirvetuximab soravtansine, a FRα-targeting antibody-drug conjugate (ADC), in relapsed epithelial ovarian cancer patients. GYNECOLOGIC ONCOLOGY[Internet]. 2017;145(-):0-0. Available from: https://sid.ir/paper/746569/en
IEEE:
Copy, “Characterization of folate receptor alpha (FRα ) expression in archival tumor and biopsy samples in a phase I study of mirvetuximab soravtansine, a FRα-targeting antibody-drug conjugate (ADC), in relapsed epithelial ovarian cancer patients,” GYNECOLOGIC ONCOLOGY, vol. 145, no. -, pp. 0–0, 2017, [Online]. Available: https://sid.ir/paper/746569/en